Ingevity (NYSE:NGVT) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $56.5, a high estimate of $62.00, and a low estimate of $50.00. This current average has increased by 16.49% from the previous average price target of $48.50.

Analyzing Analyst Ratings: A Detailed Breakdown

In examining recent analyst actions, we gain insights into how financial experts perceive Ingevity. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ingevity's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Ingevity analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Ingevity

Ingevity: Delving into Financials

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Negative Revenue Trend: Examining Ingevity's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -13.37% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.

Net Margin: Ingevity's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -16.47% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Ingevity's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -9.34%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.16%, the company may need to address challenges in generating satisfactory returns from its assets.

Debt Management: Ingevity's debt-to-equity ratio stands notably higher than the industry average, reaching 2.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Understanding the Relevance of Analyst Ratings

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

This article was generated by Benzinga's automated content engine and reviewed by an editor.